ASCO

News

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of

Oncology

Oncology 2023

Oncology 2023 features interviews, analysis, and commentary from pharmaphorum, industry leaders, and more

News

J&J files Carvykti for earlier use in multiple myeloma

As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo

News

ASCO: Enhertu data sets up tumour-agnostic label bid

AstraZeneca and Daiichi Sankyo’s Enhertu is already gathering momentum as a treatment for HER2-positive and HER2-low breast, gastric, and lung cancer, but new data could b

News

ASCO: Moderna, Merck melanoma vaccine set for phase 3

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase

News

ASCO: Vorasidenib shows its glioma potential in INDIGO

Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

Oncology 2023

J&J files Carvykti for earlier use in multiple myeloma

ASCO: Enhertu data sets up tumour-agnostic label bid

ASCO: Moderna, Merck melanoma vaccine set for phase 3

ASCO: Vorasidenib shows its glioma potential in INDIGO

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

ASCO

Editor's Picks